在新发病的ACHR亚型一般化肌痛症患者中,efgartigimod与治疗标准:前性队列研究
Dingxian He1, Lei Jin1, Shuangshuang Wang2
1Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai 200040, China.
Clinical immunology (Orlando, Fla.)
|August 23, 2025
概括
在12周内,Efgartigimod (EFG) 显著改善了新发病的一般化肌痛性肌痛症患者的最小症状表现. 这表明EFG是早期GMG快速疾病控制的有希望的选择.
科学领域:
- 神经学
- 免疫学
- 药理学
背景情况:
- 一般化肌痛性肌痛 (gMG) 是一种慢性自身免疫性疾病,影响神经肌肉结节.
- Efgartigimod (EFG) 已被批准用于长期疾病的gMG,但其在新发病例中的有效性尚不清楚.
研究的目的:
- 评估efgartigimod (EFG) 在新发病的一般化肌痛性肌痛症 (gMG) 患者的疗效.
主要方法:
- 一项涉及87名新发性GMG患者的队列研究.
- 患者接受了常规治疗 (类固醇,免疫抑制剂) 或常规治疗加EFG.
- 在4周以上的时间内,通过MG-ADL (Myasthenia Gravis Activities of Daily Living) 得分为0或1的最低症状表现 (MSE) 响应者被评估为12周.
主要成果:
- 与传统组 (13. 33%) 相比,EFG组在12周内出现了显著更高的MSE反应比例 (p=0. 0026).
- 在EFG组中,晚期发生的gMG患者的MG- ADL降低比胸腺瘤相关的gMG患者更大 (p=0. 040).
结论:
- 在新发病的一般性肌痛性肌痛症 (gMG) 中,efgartigimod (EFG) 显示出快速控制疾病的潜力.
- 需要进一步的研究来证实EFG在该患者群体中的长期安全性和成本效益.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
828
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
828
Direct-Acting Cholinergic Agonists: Therapeutic Uses
873
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
873
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
647
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
647


